275 related articles for article (PubMed ID: 8473515)
1. Gene p53 mutations are restricted to poorly differentiated and undifferentiated carcinomas of the thyroid gland.
Donghi R; Longoni A; Pilotti S; Michieli P; Della Porta G; Pierotti MA
J Clin Invest; 1993 Apr; 91(4):1753-60. PubMed ID: 8473515
[TBL] [Abstract][Full Text] [Related]
2. Unique association of p53 mutations with undifferentiated but not with differentiated carcinomas of the thyroid gland.
Ito T; Seyama T; Mizuno T; Tsuyama N; Hayashi T; Hayashi Y; Dohi K; Nakamura N; Akiyama M
Cancer Res; 1992 Mar; 52(5):1369-71. PubMed ID: 1737400
[TBL] [Abstract][Full Text] [Related]
3. Contribution of p53 gene alterations to development of metastatic forms of follicular thyroid carcinoma.
Sápi Z; Lukács G; Sztán M; Papp J; Oláh E
Diagn Mol Pathol; 1995 Dec; 4(4):256-60. PubMed ID: 8634781
[TBL] [Abstract][Full Text] [Related]
4. Prevalence of mutations of ras and p53 in benign and malignant thyroid tumors from children exposed to radiation after the Chernobyl nuclear accident.
Nikiforov YE; Nikiforova MN; Gnepp DR; Fagin JA
Oncogene; 1996 Aug; 13(4):687-93. PubMed ID: 8761289
[TBL] [Abstract][Full Text] [Related]
5. ras mutations are associated with aggressive tumor phenotypes and poor prognosis in thyroid cancer.
Garcia-Rostan G; Zhao H; Camp RL; Pollan M; Herrero A; Pardo J; Wu R; Carcangiu ML; Costa J; Tallini G
J Clin Oncol; 2003 Sep; 21(17):3226-35. PubMed ID: 12947056
[TBL] [Abstract][Full Text] [Related]
6. [Unique association of p53 mutations with undifferentiated carcinoma of the thyroid].
Ito T; Seyama T; Hayashi Y; Dohi K; Akiyama M
Nihon Rinsho; 1994 Apr; 52(4):1069-74. PubMed ID: 8196165
[TBL] [Abstract][Full Text] [Related]
7. Molecular genetic alterations of FHIT and p53 genes in benign and malignant thyroid gland lesions.
Pavelić K; Dedivitis RA; Kapitanović S; Cacev T; Guirado CR; Danić D; Radosević S; Brkić K; Pegan B; Krizanac S; Kusić Z; Spaventi S; Bura M
Mutat Res; 2006 Jul; 599(1-2):45-57. PubMed ID: 16698048
[TBL] [Abstract][Full Text] [Related]
8. Mutation of the p53 gene in a differentiated human thyroid carcinoma cell line, but not in primary thyroid tumours.
Wright PA; Lemoine NR; Goretzki PE; Wyllie FS; Bond J; Hughes C; Röher HD; Williams ED; Wynford-Thomas D
Oncogene; 1991 Sep; 6(9):1693-7. PubMed ID: 1923534
[TBL] [Abstract][Full Text] [Related]
9. Aberrations of the p53 tumor suppressor gene in human epithelial ovarian carcinoma.
Kim JW; Cho YH; Kwon DJ; Kim TE; Park TC; Lee JM; Namkoong SE
Gynecol Oncol; 1995 May; 57(2):199-204. PubMed ID: 7729734
[TBL] [Abstract][Full Text] [Related]
10. Genetic mutations in thyroid carcinoma.
Taccaliti A; Boscaro M
Minerva Endocrinol; 2009 Mar; 34(1):11-28. PubMed ID: 19209125
[TBL] [Abstract][Full Text] [Related]
11. Expression and mutation analysis of the tyrosine kinase c-kit in poorly differentiated and anaplastic thyroid carcinoma.
Broecker-Preuss M; Sheu SY; Worm K; Feldkamp J; Witte J; Scherbaum WA; Mann K; Schmid KW; Schott M
Horm Metab Res; 2008 Oct; 40(10):685-91. PubMed ID: 18622894
[TBL] [Abstract][Full Text] [Related]
12. Homozygous proline at codon 72 of p53 as a potential risk factor favoring the development of undifferentiated thyroid carcinoma.
Boltze C; Roessner A; Landt O; Szibor R; Peters B; Schneider-Stock R
Int J Oncol; 2002 Nov; 21(5):1151-4. PubMed ID: 12370767
[TBL] [Abstract][Full Text] [Related]
13. Genetic and epigenetic alterations of the cyclin-dependent kinase inhibitors p15INK4b and p16INK4a in human thyroid carcinoma cell lines and primary thyroid carcinomas.
Elisei R; Shiohara M; Koeffler HP; Fagin JA
Cancer; 1998 Nov; 83(10):2185-93. PubMed ID: 9827724
[TBL] [Abstract][Full Text] [Related]
14. [Poorly differentiated carcinoma of the thyroid--immunohistochemical evaluation of p53 and p27 protein expression].
Wierzchowski W; Szybiński P; Nowak W; Nowak K; Szybiński Z; Buziak-Bereza M; Stachura J
Wiad Lek; 2001; 54 Suppl 1():79-87. PubMed ID: 12182066
[TBL] [Abstract][Full Text] [Related]
15. Expression of bcl-2, c-erbB-2, p53, and p21 (waf1-cip1) protein in thyroid carcinomas.
Soda G; Antonaci A; Bosco D; Nardoni S; Melis M
J Exp Clin Cancer Res; 1999 Sep; 18(3):363-7. PubMed ID: 10606183
[TBL] [Abstract][Full Text] [Related]
16. Hybrid carcinomas of the salivary glands: report of nine cases with a clinicopathologic, immunohistochemical, and p53 gene alteration analysis.
Nagao T; Sugano I; Ishida Y; Asoh A; Munakata S; Yamazaki K; Konno A; Iwaya K; Shimizu T; Serizawa H; Ebihara Y
Mod Pathol; 2002 Jul; 15(7):724-33. PubMed ID: 12118110
[TBL] [Abstract][Full Text] [Related]
17. p53 in a thyroid follicular carcinoma with foci of poorly differentiated and anaplastic carcinoma.
Matias-Guiu X; Villanueva A; Cuatrecasas M; Capella G; De Leiva A; Prat J
Pathol Res Pract; 1996 Dec; 192(12):1242-9; discussion 1250-1. PubMed ID: 9182295
[TBL] [Abstract][Full Text] [Related]
18. High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas.
Fagin JA; Matsuo K; Karmakar A; Chen DL; Tang SH; Koeffler HP
J Clin Invest; 1993 Jan; 91(1):179-84. PubMed ID: 8423216
[TBL] [Abstract][Full Text] [Related]
19. [Clinicopathological study on primary lung cancer--immunohistochemical expression of p53 suppressor gene and bcl-2 oncogene in relation to prognosis].
Irie K; Ishida H; Furukawa T; Koyanagi K; Miyamoto Y
Rinsho Byori; 1996 Jan; 44(1):32-41. PubMed ID: 8691638
[TBL] [Abstract][Full Text] [Related]
20. p53 mutations in multiple urothelial carcinomas: a molecular analysis of the development of multiple carcinomas.
Goto K; Konomoto T; Hayashi K; Kinukawa N; Naito S; Kumazawa J; Tsuneyoshi M
Mod Pathol; 1997 May; 10(5):428-37. PubMed ID: 9160306
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
